Drug Trial Radar · NCT07639242
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 21, 2030
Study completion Jun 21, 2030
Sponsor
- Lead sponsor
- UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has a Kirsten Rat Sarcoma Virus (KRAS) G12C mutation and a programmed death-ligand (PD-L1) score between 1% and 49%. The main goal of the study is to determine how long patients live without their cancer worsening after starting treatment, also known as progression-free survival (PFS). Additional goals include evaluating how many patients experience tumor shrinkage or disappearance, how long responses to treatment last, overall survival, and the safety and side effects of the treatment combination. Furthermore, how well the treatment works in patients whose cancer has spread to the brain, outcomes in patients with a lower Eastern Cooperative Oncology Group performance status (ECOG), and whether certain tumor or blood-based biomarkers are associated with treatment response or side effects, if enough patient data is available for analysis.
Conditions
- Lung Cancer
- Lung Cancer (NSCLC)
- Locally Advanced NSCLC
- Metastatic NSCLC - Non-Small Cell Lung Cancer
Interventions
OlomorasibDrug
Olomorasib 100 mg tb, twice a day
PembrolizumabDrug
200 mg, 30-minute IV infusion in every 3 weeks for first 12 cycles or 395 mg for first 12 cycles Sub-cutaneous in abdomen or thigh
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.